MapLight Therapeutics, Inc. (MPLT) - 10-K Summary
Business Context and Reporting Period
Company: MapLight Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: MapLight is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for central nervous system (CNS) disorders. The company utilizes a discovery platform combining optogenetics, single-cell transcriptomics, and spatial transcriptomics to identify neural circuits linked to disease.
Key Milestones: In October 2025, the company completed its Initial Public Offering (IPO) on the Nasdaq Global Select Market. In December 2025, its lead candidate, ML-007C-MA, received FDA Fast Track designation for Alzheimer's Disease Psychosis (ADP).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(161.2) | $(77.6) |
| Operating Expenses | $169.1 | $82.9 |
| Cash, Cash Equivalents & Investments | $453.1 | $119.8 |
| Accumulated Deficit | $(360.5) | $(199.4) |
| Net Cash Used in Operating Activities | $(138.1) | $(78.8) |
Note: The company has no revenue and is not profitable. Expenses are primarily driven by research and development (R&D) and general and administrative (G&A) costs.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss more than doubled from $77.6 million in 2024 to $161.2 million in 2025. This was driven by a $69.8 million increase in R&D expenses and a $16.3 million increase in G&A expenses.
- R&D Expense Drivers: The increase in R&D was primarily due to a $35.3 million rise in clinical trial expenses (initiation of Phase 2 trials) and a $29.7 million increase in employee-related expenses, largely due to $21.6 million in stock-based compensation from IPO-related vesting.
- Liquidity Position: Cash and investments increased significantly to $453.1 million as of December 31, 2025, compared to $119.8 million in 2024. This was fueled by net proceeds of $261.6 million from the IPO and $7.5 million from a concurrent private placement.
- Capital Structure: All outstanding redeemable convertible preferred stock converted to common stock upon the closing of the IPO in October 2025.
Guidance, Outlook, and Risks
Clinical Pipeline Outlook:
- ML-007C-MA (Schizophrenia & ADP): Phase 2 ZEPHYR trial (Schizophrenia) expects topline results in Q3 2026. Phase 2 VISTA trial (ADP) expects topline results in H2 2027.
- ML-004 (Autism Spectrum Disorder): Phase 2 IRIS trial enrollment is complete; topline results expected in Q3 2026.
Liquidity and Capital Resources: Based on current operational plans, management believes existing cash, cash equivalents, and investments ($453.1 million) are sufficient to fund operations through 2027. The company expects to incur substantial losses for the foreseeable future and will require additional capital to complete clinical development and commercialization.
Key Risks and Contingencies:
- Regulatory Uncertainty: Clinical development is lengthy and expensive. The company previously experienced FDA clinical holds (lifted in 2024) and faces risks regarding trial design, patient enrollment, and regulatory approval.
- Capital Requirements: Failure to obtain additional capital on acceptable terms could force the company to delay, limit, or terminate product development.
- Third-Party Reliance: The company relies entirely on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) for manufacturing and clinical trials.
- Intellectual Property: Success depends on maintaining patent protection, which may be challenged or expire before commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $453.1 million cash balance against the projected burn rate for 2026-2027, considering potential delays in clinical trials.
- Clinical Trial Progress: Monitor enrollment rates and safety data for the ZEPHYR (Schizophrenia) and VISTA (ADP) Phase 2 trials, as well as the IRIS (ASD) trial.
- Regulatory Status: Confirm the status of the FDA Fast Track designation for ML-007C-MA and any potential new clinical holds or regulatory feedback.
- Stock-Based Compensation: Assess the impact of future equity grants and vesting schedules on future operating expenses and shareholder dilution.
- Manufacturing Supply Chain: Evaluate the stability and capacity of third-party CMOs, particularly given the reliance on single-source suppliers for certain components.